Aberdeen Group plc Purchases Shares of 1,021,063 Taysha Gene Therapies, Inc. $TSHA

Key Points

• Aberdeen Group bought 1,021,063 new shares of Taysha in Q4 (≈$5.62M), giving Aberdeen about a 0.37% stake while institutional investors now own roughly 77.7% of the company.
• Several analysts have raised price targets (e.g., Canaccord to $17), and the consensus rating is a Buy with an average target price of $11.64.
• Despite a quarter that beat estimates (EPS -$0.08 vs. -$0.11; revenue $5.49M vs. $1.89M), insiders sold about 598,623 shares in the last three months and now own 3.78% of the stock.

Aberdeen Group plc purchased a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,021,063 shares of the company's stock, valued at approximately $5,616,000. Aberdeen Group plc owned about 0.37% of Taysha Gene Therapies as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC acquired a new stake in shares of Taysha Gene Therapies in the third quarter worth $1,890,000. Ally Bridge Group NY LLC acquired a new stake in shares of Taysha Gene Therapies in the third quarter worth $6,207,000. GSA Capital Partners LLP grew its stake in shares of Taysha Gene Therapies by 969.0% in the third quarter. GSA Capital Partners LLP now owns 477,749 shares of the company's stock worth $1,562,000 after acquiring an additional 433,059 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $1,697,000. Finally, SG Americas Securities LLC grew its stake in shares of Taysha Gene Therapies by 2,271.8% in the fourth quarter. SG Americas Securities LLC now owns 781,474 shares of the company's stock worth $4,298,000 after acquiring an additional 748,525 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Analysts Set New Price Targets

TSHA has been the topic of several research analyst reports. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday. Needham & Company LLC raised their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Thursday, March 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Chardan Capital restated a "buy" rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Finally, Truist Financial upgraded shares of Taysha Gene Therapies to a "strong-buy" rating in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $11.64.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company's stock, valued at approximately $4,740,327.69. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $375,098.00. Following the transaction, the chief financial officer directly owned 1,467,635 shares of the company's stock, valued at approximately $6,971,266.25. The trade was a 5.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is currently owned by company insiders.

Taysha Gene Therapies Stock Down 0.4%

TSHA opened at $4.55 on Thursday. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The firm's fifty day moving average price is $4.54 and its two-hundred day moving average price is $4.67. The company has a market capitalization of $1.31 billion, a P/E ratio of -13.38 and a beta of 1.10.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. On average, analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.